7LAD
Clobetasol propionate bound to CYP3A5
7LAD の概要
エントリーDOI | 10.2210/pdb7lad/pdb |
分子名称 | Cytochrome P450 3A5, PROTOPORPHYRIN IX CONTAINING FE, Clobetasol propionate, ... (4 entities in total) |
機能のキーワード | cytochrome p450, cyp3a5, membrane protein |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 1 |
化学式量合計 | 56153.22 |
構造登録者 | Buchman, C.D.,Miller, D.,Wang, J.,Jayaraman, S.,Chen, T. (登録日: 2021-01-06, 公開日: 2021-10-27, 最終更新日: 2023-10-18) |
主引用文献 | Wang, J.,Buchman, C.D.,Seetharaman, J.,Miller, D.J.,Huber, A.D.,Wu, J.,Chai, S.C.,Garcia-Maldonado, E.,Wright, W.C.,Chenge, J.,Chen, T. Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5. J.Am.Chem.Soc., 143:18467-18480, 2021 Cited by PubMed Abstract: The human cytochrome P450 (CYP) CYP3A4 and CYP3A5 enzymes metabolize more than one-half of marketed drugs. They share high structural and substrate similarity and are often studied together as CYP3A4/5. However, CYP3A5 preferentially metabolizes several clinically prescribed drugs, such as tacrolimus. Genetic polymorphism in makes race-based dosing adjustment of tacrolimus necessary to minimize acute rejection after organ transplantation. Moreover, the differential tissue distribution and expression levels of CYP3A4 and CYP3A5 can aggravate toxicity during treatment. Therefore, selective inhibitors of CYP3A5 are needed to distinguish the role of CYP3A5 from that of CYP3A4 and serve as starting points for potential therapeutic development. To this end, we report the crystal structure of CYP3A5 in complex with a previously reported selective inhibitor, clobetasol propionate (CBZ). This is the first CYP3A5 structure with a type I inhibitor, which along with the previously reported substrate-free and type II inhibitor-bound structures, constitute the main CYP3A5 structural modalities. Supported by structure-guided mutagenesis analyses, the CYP3A5-CBZ structure showed that a unique conformation of the F-F' loop in CYP3A5 enables selective binding of CBZ to CYP3A5. Several polar interactions, including hydrogen bonds, stabilize the position of CBZ to interact with this unique F-F' loop conformation. In addition, functional and biophysical assays using CBZ analogs highlight the importance of heme-adjacent moieties for selective CYP3A5 inhibition. Our findings can be used to guide further development of more potent and selective CYP3A5 inhibitors. PubMed: 34648292DOI: 10.1021/jacs.1c07066 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.65 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード